drugset / Trial / NCT00119730
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
Phase 2
Completed
30 enrolled
Dana-Farber Cancer Institute
Biogen · collabMassachusetts General Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
* The purpose of this study is to find out whether combining a short course of chemotherapy (Fludarabine, Mitoxantrone and Rituximab) followed by Zevalin will be effective in treating relapsed mantle cell lymphoma. * The secondary purposes of the study are to determine the safety and to evaluate whether there is additional benefit from Zevalin therapy following the chemotherapy.
Timeline
- Start
- 2005-02
- Primary completion
- 2006-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fludarabine | Small molecule | — | — |
| Subject | Mitoxantrone | Small molecule | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |
| Subject | ibritumomab tiuxetan | Monoclonal antibody | — | — |